AtriCure, Inc. Form 8-K August 21, 2017		
August 21, 2017		
UNITED STATES		
SECURITIES AND EXCHANGE COMMISSION	ON	
WASHINGTON, D.C. 20549		
FORM 8-K		
CURRENT REPORT		
PURSUANT TO SECTION 13 OR 15(d) of the		
SECURITIES EXCHANGE ACT OF 1934		
Date of Report (Date of earliest event reported):	August 18, 2017	
ATRICURE, INC.		
(Exact name of registrant as specified in charter)		
Delaware	000-51470	34-1940305
(State or other jurisdiction of incorporation)		

Edgar Filing: AtriCure, Inc. - Form 8-K

7555 Innovation Way

Mason, OH 45040

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (513) 755-4100

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Edgar Filing: AtriCure, Inc. - Form 8-K

Item 7.01.Regulation FD Disclosure

On August 18, 2017, AtriCure, Inc. (the "Company") posted an investor presentation on its website http://ir.atricure.com. A copy of the investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The Company's presentation discloses certain financial results both in accordance with generally accepted accounting principles ("GAAP") and on a non-GAAP basis with adjustments for certain items. The Company's management believes that presentation of these non-GAAP financial measures and their related reconciliations are useful to investors because the non-GAAP financial measures provide investors with a basis for comparing the results to financial results from prior periods.

Information in the presentation contains forward-looking statements regarding future events and performance of the Company. All such forward-looking statements are based largely on the Company's experience and perception of current conditions, trends, expected future developments and other factors, and on management's expectations, and are subject to risks and uncertainties that could cause actual results to differ materially, including, but not limited to, those factors described in the presentation and in the Company's filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any financial or other projections or other forward-looking statements, whether because of new information, future events or otherwise.

The information in Item 7.01 of this Form 8-K and in the presentation attached as Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in Item 7.01 of this Form 8-K and Exhibit 99.1 shall not be incorporated by reference in any filing (whether made before or after the date hereof) or any other document under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing or document.

Item 9.01Financial Statements and Exhibits.

- (d) Exhibits
- No. Description
- 99.1 Investor Presentation

Edgar Filing: AtriCure, Inc. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATRICURE, INC.

Dated: August 18, 2017 By: /s/ M. Andrew Wade

M. Andrew Wade

Senior Vice President and Chief Financial Officer